Feng Z - Search Results

1

CYP17 polymorphisms and prostate cancer outcomes.

Wright JL, Kwon EM, Lin DW, Kolb S, Koopmeiners JS, Feng Z, Ostrander EA, Stanford JL. Wright JL, et al. Among authors: feng z. Prostate. 2010 Jul 1;70(10):1094-101. doi: 10.1002/pros.21143. Prostate. 2010. PMID: 20503394 Free PMC article.

2

Lactose and galactose intake and metabolism in relation to the risk of epithelial ovarian cancer.

Herrinton LJ, Weiss NS, Beresford SA, Stanford JL, Wolfla DM, Feng Z, Scott CR. Herrinton LJ, et al. Among authors: feng z. Am J Epidemiol. 1995 Mar 1;141(5):407-16. doi: 10.1093/oxfordjournals.aje.a117443. Am J Epidemiol. 1995. PMID: 7879785

3

Lactose metabolism and time to pregnancy.

Herrinton LJ, Lemaitre RN, Beresford SA, Stanford JL, Wolfla DM, Feng Z, Scott CR, Weiss NS. Herrinton LJ, et al. Among authors: feng z. Fertil Steril. 1996 Sep;66(3):384-8. Fertil Steril. 1996. PMID: 8751734 Free article.

4

Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study.

Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. Stanford JL, et al. Among authors: feng z. JAMA. 2000 Jan 19;283(3):354-60. doi: 10.1001/jama.283.3.354. JAMA. 2000. PMID: 10647798

5

A polymorphism in the CYP17 gene and risk of prostate cancer.

Stanford JL, Noonan EA, Iwasaki L, Kolb S, Chadwick RB, Feng Z, Ostrander EA. Stanford JL, et al. Among authors: feng z. Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):243-7. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 11895872

6

General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study.

Penson DF, Feng Z, Kuniyuki A, McClerran D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL, Stanford JL. Penson DF, et al. Among authors: feng z. J Clin Oncol. 2003 Mar 15;21(6):1147-54. doi: 10.1200/JCO.2003.07.139. J Clin Oncol. 2003. PMID: 12637483

7

Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study.

Stanford JL, Sabacan LP, Noonan EA, Iwasaki L, Shu J, Feng Z, Ostrander EA. Stanford JL, et al. Among authors: feng z. Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):876-81. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 14504198

8

Vitamin D receptor gene polymorphisms and prostate cancer risk.

Cheteri MB, Stanford JL, Friedrichsen DM, Peters MA, Iwasaki L, Langlois MC, Feng Z, Ostrander EA. Cheteri MB, et al. Among authors: feng z. Prostate. 2004 Jun 1;59(4):409-18. doi: 10.1002/pros.20001. Prostate. 2004. PMID: 15065089

9

5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study.

Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL. Penson DF, et al. Among authors: feng z. J Urol. 2005 May;173(5):1701-5. doi: 10.1097/01.ju.0000154637.38262.3a. J Urol. 2005. PMID: 15821561

10

Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis.

Agalliu I, Lin DW, Salinas CA, Feng Z, Stanford JL. Agalliu I, et al. Among authors: feng z. Prostate. 2006 Oct 1;66(14):1535-41. doi: 10.1002/pros.20491. Prostate. 2006. PMID: 16921513

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10,327 results

Search Page